Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Prescriber's Choice and Sincerus FL Release a Statement Regarding Allergan Lawsuit | ||
| By: PR Newswire Association LLC. - 20 Sep 2017 | Back to overview list |
|
POMPANO BEACH, Fla., Sept. 20, 2017 /PRNewswire/ -- Prescriber's Choice Inc. and Sincerus FL, LLC, two companies formed with the goal of providing physicians and patients access to high quality, safe, and affordable medications, responded to a press release issued by Allergan® plc (AGN) regarding a lawsuit Allergan USA Inc. filed against the them: Prescriber's Choice and Sincerus FL will vigorously defend ourselves against this baseless attack and will prevail against this or any other any attempt by Allergan to bully us and deter safe innovation for doctors and patients. Through the services provided by each of these Companies, physicians can dispense customized medications at the time of their patients' appointment, typically for less than their insurance copayment. This provides a practical means for physicians to prescribe and dispense in a manner that they feel is best for their patients without the restrictions placed by third party payors or the pricing constraints set by companies such as Allergan. This lawsuit is merely an attempt to eliminate competition and is a continuation of their rent-seeking behavior. Nothing is more important to Prescriber's Choice and Sincerus FL than patient well-being and safety. Sincerus FL was last inspected by the FDA, the appropriate regulatory body, in June of 2017. Their findings are made public and can be found on their website. The allegations made by Allergan are unfounded and confusing. Under Federal law, Sincerus FL is exempt from the New Drug Application process or the amended NDA. Sincerus FL is a registered 503B Outsourcing Facility and is required to follow current Good Manufacturing Practices (CGMP) guidelines for outsourcing facilities. 503B Outsourcing Facilities were created by Congress and the FDA under the Drug Quality and Security Act to open access to necessary medications that are made under strict quality standards. Prescriber's Choice and Sincerus FL innovate in a way that can potentially save the American Consumer billions. By democratizing the drug delivery business these companies are an answer to America's second largest drug problem - medication adherence. Drugs that are unaffordable are most often not filled, therefore, cannot be effective. Prescriber's Choice consults with physicians in creating their own formulary, and physicians can then alter potencies or change medication delivery modalities and combine different active pharmaceutical ingredients to improve medication compliance, adherence, and outcomes. Please direct media inquiries to: mediarequests@prescriberschoice.com
View original content:http://www.prnewswire.com/news-releases/prescribers-choice-and-sincerus-fl-release-a-statement-regarding-allergan-lawsuit-300522999.html SOURCE Prescriber's Choice; Sincerus FL 
|
||
|
||
 | Back to overview list | |